|Application ||WB, IHC-P, E|
|Other Accession||AAI09386, 14211875|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||9232 Da|
|Application Notes||ECRG2 antibody can be used for detection of ECRG2 by Western blot at 1 µg/mL. Antibody can also be used for immunohistochemistry starting at 5 µg/mL.|
|Target/Specificity||SPINK7; ECRG2 antibody is predicted to not cross-react with other ECRG family members|
|Reconstitution & Storage||ECRG2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||ECRG2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Probable serine protease inhibitor.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
ECRG2 Antibody: The esophageal cancer-susceptibility gene 2 (ECRG2), also known as SPINK7, is a novel tumor suppressor gene identified from the human esophagus. It interacts directly with metallothionein 2A and urokinase-type plasminogen activator (uPA), and downregulates the activity of uPA, leading to reduced cancer cell migration, invasion and metastasis. ECRG2 forms a complex with uPA and its receptor uPAR, modifying the dynamic association of uPAR with beta1 integrins and disrupting the Src/MAP kinase pathway that normally stimulates cell migration and invasion. ECRG2 may thus represent a novel therapeutic target for cancer.
Cui Y, Wang J, Zhang X, et al. ECRG2, a novel candidate of tumor suppressor gene in the esophageal carcinoma, interacts directly with metallothionein 2A and links to apoptosis. Biochem. Biophys. Res. Commun. 2003; 302:904-15.
Huang G, Hu Z, Li M, et al. ECRG2 inhibits cancer cell migration, invasion and metastasis through the down-regulation of uPA/plasmin activity. Carcinogenesis 2007; 28:2274-81
Cheng X, Shen Z, Yin L, et al. ECRG2 regulates cell migration/invasion through the urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway. J. Biol. Chem. 2009; 284:30897-906
If you have any additional inquiries please email technical services at firstname.lastname@example.org.